LOS ANGELES – Tiger Group will be holding an online auction on Dec. 9 of late-model equipment surplus to the ongoing operations of a leading CBD and cannabis manufacturer.
The auction features well-maintained equipment, including:
2017 Agilent lntuvo 9000 Gas Chromatography System, complete with 7697A Headspace Sampler
2017 Agilent Ultivo Triple Quadrupole LC/MS System
2018 Tuttnaur Autoclave, Model EZ11-Plus
Laminar Flow Station
2017 Waters Preparatory System, Model SFC 350
“We are pleased to be selling late-model equipment from this industry-leading company that can crossover to multiple industries, including CBD, pharmaceutical and industrial,” noted Jonathan Holiday, Director of Business Development, Tiger Commercial & Industrial. “Many of these assets have had minimal usage and were purchased just in the past few years. As the CBD industry heads into 2021 with a far more positive outlook, this sale presents an excellent opportunity for companies to buy manufacturing equipment that will help meet the anticipated rise in demand.”
Online bidding at SoldTiger.com will close on Wednesday, December 9, at 10:30 a.m. (PT). All bidders are required to register prior to the sale at SoldTiger.com.
Previews are available by appointment only on Tuesday, December 8, from 10 a.m. to 4 p.m. (ET) in Utica, New York, and 10 to 4 p.m. (PT) in Sparks, Nevada.
To arrange an appointment, contact Jonathan Holiday at (805) 367-3893, [email protected].
Long before Christmas was all about the birth of Jesus Christ it was a celebration of the winter solstice, the longest night of the year, which falls between December 21 and 22. Pre-Christian people of Europe, often referred to as pagans, were intimately connected with the seasons and depended on the return of the sun—and plants—for survival. Though harsh winter months lay ahead, ancient Europeans turned the long, dark nights of late December into a party, known as Yule.
“Yule is the Germanic term for winter solstice,” explained Dr. Chris Klassen, religion and culture professor at Wilfrid Laurier University in Waterloo, Ontario. (“Germanic” being a loose term that includes most people of Europe in the past).
Because the days grow steadily longer after the winter solstice, ancient Yule celebrations were all about the returning sun. “Evergreen trees and boughs and wreathes were about bringing green—a symbol of spring and summer—into the home to remember life is being reborn,” said Klassen. “And of course Yule logs, which for ancient pagans were actual logs burning in the fireplace through the longest night, rather than cake.”
While belief systems have changed over the centuries, plants continue to play a central role at Christmastime: evergreens, holly, mistletoe, cinnamon, cloves, oranges, nuts, gingerbreads, potpourri—and even cannabis—are all carryovers from old traditions. Here are some of the historic ways cannabis brought symbolic green, good vibes, and festive merriment to the darkest days of the year.
Before they were the 12 Days of Christmas—Dec. 25 to Jan. 6—they were twelve “raw nights” when the pre-Christian god Wotan (Odin or Wodan) and his wild army galloped across the sky fighting a battle between light and darkness, also known as the Wild Hunt.
Not only did Wotan and his legion pluck unsuspecting people off the ground, but other lurking demons could surface on these long winter nights, too. To calm the gods and ward away evil before bedtime, pagans and early Christians smudged their homes and stables with an auspicious number of nine herbs, such as juniper, evergreen resins, milk thistle, mugwort, and likely cannabis, wrote Christian Rästch in Pagan Christmas.
Today, Catholic masses continue to burn terpene-rich frankincense on Christmas Eve, and some speculate the Wild Hunt is a foundational story of Santa and his reindeer flying through the sky.
“The stump of a pipe he held tight in his teeth / And the smoke, it encircled his head like a wreath,” wrote Clement Clarke Moore in his 1823 poem, A Visit from St. Nicholas (aka ‘Twas the Night Before Christmas).
The jolly, pipe-smoking Santa icon harkens back to an bygone era of smoking of not just tobacco, but baccy: a pungent mixture of forest and meadow herbs smoked at Christmastime that often contained cannabis, according to Rästch. In Pagan Christmas, he wrote that Germans had a special word for the pop of cannabis seeds in their Christmas baccy, which they called knastert.
Rästch speculates the pipe-smoking, pagan mountain spirit Rübezahl was a precursor to the benevolent St. Nicholas, who later gave rise to the punishing Ru-klaus (“Rough Nicholas”) and the terrifying Krampus. Thanks to the creative work of 19th-century American poets like Moore, children today look forward to visits from a very merry Santa Claus, possibly kept in good humor by the contents of his pipe.
Many craft brewers today brew a limited-run Christmas ale or winter beer loaded up with herbs and spices, a centuries-old tradition tied to Yule. Northern Germanic cultures were especially fond of Julbeers—Norway even imposed a law in the 10th century stipulating every household brew their own beer for Yule or face heavy fines.
and toss in extra intoxicants at Yuletide for the warm fuzzies: cannabis, wormwood, and black henbane, along with fir greens and wild rosemary for flavor.
Hemp seed soup
In The Great Book of Hemp, Rowan Robinson writes of an old Christmas Eve tradition still seen in Poland and Lithuania today: semieniatka, or hemp seed soup, is offered to deceased family members who come back to visit their families over the holidays.
Robinson speculates the custom stretches back to ancient Scythian culture where cannabis was inextricably linked to rituals surrounding death and funerals.
Note: Scythians can also be grouped as pagans, which Klassen says means “people of the countryside,” used by Roman Christians to describe anyone who hadn’t converted.
Special mention: Fly agaric mushroom
Ever notice red and white mushrooms on old-timey Christmas illustrations? This is the fly agaric mushroom, or Amanita muscaria, a psychedelic fungus with ancient associations with the winter solstice. Many iterations of the Wild Hunt describe fly agaric mushrooms growing wherever Wotan rode through the clouds, which magically sprout nine months later, from the autumn equinox (September 21) to the end of December.
In the northernmost regions of Europe and Siberia, shamans are said to have eaten fly agaric mushrooms at the winter solstice. Until recently, scholars say indigenous Sami people of Lapland waited in their tents on the longest night for a shaman to arrive on a reindeer-drawn sled. Inside, he would consume fly agaric mushrooms
and bestow “gifts” of healing and advice from another realm onto the family, who would then feed the holy man for his service. These well-fed shamans dressed in red and white to honor the power and magic of these mushrooms, which allegedly gave people the sensation of flying through the sky.
Colleen Fisher Tully
Colleen Fisher Tully is a freelance writer and editor with recent work in Clean Eating, Today’s Parent, The Walrus and Local Love. She posts random thoughts on Twitter @colleenftully
Second- and thirdhand tobacco smoke have received lots of attention, but much less is known about the compounds deposited on surfaces from cannabis smoke. Now, researchers reporting in ACS’ Environmental Science & Technology have discovered that ozone –a component of outdoor and indoor air — can react with tetrahydrocannabinol (THC), the psychoactive component of cannabis, on glass or cotton surfaces to produce new compounds, which they characterized for the first time.
Smoking emits reactive chemicals that remain in the air (so-called secondhand smoke) or deposit onto surfaces, including walls, windows, clothing and upholstery (thirdhand smoke). Unlike the secondhand variety, thirdhand smoke lingers long after a person stops smoking. Nicotine is semi-volatile and reacts with other chemicals on surfaces, producing new compounds that, if volatile, can also become airborne. Because cannabis smoke is chemically distinct from tobacco smoke, Aaron Wylie and Jonathan Abbatt wanted to characterize the compounds formed when THC, by itself or in cannabis smoke, on surfaces reacts with ozone in the air.
The researchers coated glass and cotton cloth, to simulate windows and clothing, with a THC solution. Then, they exposed the surfaces to concentrations of ozone that could exist in indoor air. In their analysis, they found that over time, the amount of THC on glass and cotton decreased, while the quantities of three THC oxidation products increased. In other experiments, the team used a smoking machine to deposit cannabis smoke onto cotton. Upon exposure to ozone, the same three compounds formed at roughly the same rate as observed for the THC-coated cloth. Because of the low volatility of THC and its oxidation products, the compounds are unlikely to be emitted to the air where they could be inhaled in as large amounts as nicotine, the researchers say. They say that somebody could still be exposed to THC and its derivatives, whose health effects are unknown, if they, for example, lick their fingers after touching a surface contaminated by cannabis smoke.
The abstract that accompanies this paper can be viewed here.
The American Chemical Society (ACS) is a nonprofit organization chartered by the U.S. Congress. ACS’ mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and its people. The Society is a global leader in providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, eBooks and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a specialist in scientific information solutions (including SciFinder® and STN®), its CAS division powers global research, discovery and innovation. ACS’ main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive news releases from the American Chemical Society, contact firstname.lastname@example.org.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.
1500 E. Lake Cook Rd., Wheeling, the potential location of the village’s first recreational adult use cannabis dispensary.
Wheeling may be known for its “Restaurant Row” but the village is looking to cannabis, rather than dining-in efforts, to fill the vacant TGI Fridays space on Lake Cook Road.
TGI Fridays, a chain restaurant offering American fare in a casual sit-down dining setting, opened in Wheeling in 2007 and closed this summer amid the ongoing COVID-19 pandemic. It was located at 1500 E. Lake Cook Rd. in the Schwind Crossings shopping center just east of Weiland Road.
Due to the pandemic, other local restaurants have lost revenue due to mandated bans on indoor dining and other mitigation measures. Last week, Wheeling trustees approved health permit refunds to help cushion the blow to restaurant owners.
With less dining revenue, the village also collects less in sales taxes. According to a proposed 2020-21 fiscal year budget for Wheeling, the village will receive $2.1 million less in revenue than expected due to the pandemic.
Village plan commissioners Tuesday (Dec. 1) were expected to discuss recommending approval for a special use permit for a recreational adult use cannabis dispensary in the former TGI Fridays space. It would be the first dispensary in the village.
“Given the current [COVID-19] pandemic, it could take a significant amount of time before this location would be viable for a new restaurant tenant,” said petitioners from Mindful Illinois, LLC in a special use request for the proposed dispensary. The applicants — who also operate a dispensary in Addison — said they intend to open the Wheeling location in the first quarter of 2021.
Wheeling trustees agreed to allow recreational cannabis dispensaries, craft growers, cultivation centers and infusers as special uses in the village late last year. Dispensaries are allowed in commercial districts and manufacturers such as craft growers are allowed in industrial districts.
While the TGI Fridays property is in a commercial district, adult recreational cannabis was not approved for the specific type of district, B-1, as it is intended for small-scale neighborhood commercial uses. A text amendment to the village code would be needed in order for the special use permit to be granted. Plan commissioners were also expected to discuss the amendment during this week’s meeting.
Since recreational adult use cannabis became legal in Illinois this January, sales have been steadily increasing, from around $39 million in total sales in January to approximately $75 million in total sales in October, according to the Illinois Dept. of Financial and Professional Regulations.
Licensed recreational adult use dispensaries in the Journal & Topics coverage area include Sunnyside in Buffalo Grove, Verilife in Arlington Heights, New Age Care in Mount Prospect, Nature’s Care Co. in Rolling Meadows and Rise in Niles, according to the state. Another two dispensary companies, EarthMed and PharmaCann, have proposed opening stores in Rosemont.
This fall, the Wheeling Village Board approved plans for 1837 Craft Grow, a cannabis grower and infuser operation, at 1480 S. Wolf Rd. However, the licensing process for growers and infusers is still underway and none have been awarded yet, according to the Illinois Dept. of Agriculture.
If plans for the Wheeling dispensary move forward, Mindful Illinois, LLC, would renovate the former TGI Fridays. However, no major changes would be made to the building, according to village documents.
The dispensary would be open from 9 a.m. to 9 p.m. seven days a week. Per state law, clients would not be able to use products sold at the location on-site and there would be a security guard present during operating hours.
Although there are some residential properties near the proposed dispensary, village staff recommends approval, as the store would be located at the opposite end of the mall, with other retail stores creating a buffer for the residential area.
Trustees must also approve the plans after the plan commission meeting in order for the project to move forward.
Support local news by subscribing to the Journal & Topics in print or online.
VANCOUVER, British Columbia, Dec. 02, 2020 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sector, is pleased to provide an introduction to Dr. Alexander MacGregor, a key scientific advisor to the Company.
Pure Extracts and Dr. MacGregor are collaborating on the development of CBD infused mushroom wellness products and are researching the optimum extraction methodologies for psilocybin in order to prepare the Company to enter the psychedelic mushroom extraction space.
Dr. MacGregor is the Dean of Faculty, distinguished Professor of Biopharmaceutics and current President of the Toronto Institute of Pharmaceutical Technology (TIPT®) – North America’s premier post-graduate institute of pharmaceutical sciences, technology and research. He is also the CEO of TIPT’s parent company, Transpharm Canada Inc., which has a Health Canada Drug Establishment License, a Cannabis Drug License and a Dealer’s License issued under the Controlled Drugs and Substances Act (CDSA). Transpharm Canada conducts cannabis testing, clinical trials, drug development and is licensed to possess psychedelic drug compounds.
Dr. MacGregor is recognized as a pharmaceutical science inventor and expert in pharmaceutical technology and novel drug delivery systems. He is a recipient of several global patents in the field of medical treatments and pharmaceutical drug delivery technologies most notably from Canada, US, Australia, Europe, Latin America, China, India and Japan. His inventions have led to groundbreaking therapeutic drugs for the treatment of cancer, management of diabetes, systemic infections, and post-operative pain.
An expert in translating pharmaceutical knowledge into sustainable businesses, Dr. MacGregor was a consultant to multi-national pharmaceutical companies such as GlaxoSmithKline, Valeant, Teva, Patheon, Sun Pharma and Beijing Double-Crane Pharma. He was appointed by the Government of China as an International Advisor in the field of pharmaceutical technology and research through a nomination proffered by the City of Beijing and Beijing Double-Crane Pharmaceutical Co. (China’s third largest pharmaceutical company).
He is the author and co-author of several articles and manuscripts in the field of pharmaceutical science and technology, a founding member and Chair of the Canadian Association of Pharmaceutical Technologists (CapTech) and the founding member and past-Chair of the Toronto Pharmaceutical Ethics Committee for research in humans. He is a member of several scientific associations such as the prestigious Control Release Society (CRS), Canadian Society of Pharmaceutical Sciences (CSPS) and the American Association of Pharmaceutical Sciences (AAPS).
Dr. MacGregor received an honours degree (Magna Cum Laude-BSc) in Medical Biochemistry and Doctor of Philosophy (Ph.D.) in Clinical Pharmacology from the University of Wales and the Royal Post-Graduate Medical School London, UK.
About Pure Extracts (CSE: PULL) (XFRA: A2QJAJ) The Company features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. On September 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act and the Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020. Find out more at https://pureextractscorp.com/.
For further information please contact Empire Communications Group at (604) 343-2724.
ON BEHALF OF THE BOARD “Ben Nikolaevsky” Ben Nikolaevsky CEO and Director
The CSE has neither approved nor disapproved the contents of this press release.
This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as „will”, „may”, „should”, „anticipate”, „expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of Pure Extracts include risks detailed from time to time in the filings made by Pure Extracts under securities regulations.
DENVER, Dec. 2, 2020 /PRNewswire/ — CBD of Denver, Inc. (OTC: CBDD), a full-line CBD and Hemp oil company („CBDD”) selling Black Pearl CBD hemp products and a producer and distributor of CBD products in Switzerland today discusses the Swiss pilot program to permit temporary production and distribution of marijuana.
In June 2020 the lower house of Switzerland’s Federal Assembly approved a bill for a five-year pilot research program for the temporary production and distribution of cannabis to adults for recreational purposes. Marijuana Business Daily reported that it could lead to the normalization of cannabis in Switzerland. The pilot program is intended to provide scientific arguments for a national debate on the opportunity to legally regulate cannabis for adult consumers, according to an expert quoted in the Marijuana Business Daily article. The upper house, the Conseil des Etats approved the bill in September. The bill includes a provision that the cannabis is to be grown by Swiss farmers
„If the pilot program is successful, CBD of Denver, Inc, Rockflowr Exchange, Rockflowr Production and Rockflowr Retail could dramatically benefit by using their expertise in CBD and hemp industry to move into the very lucrative marijuana business” explained Marcel Gamma.
CBDD is focused on using equity to acquire profitable Swiss assets at attractive valuations to create value for all our shareholders
CBDD offers a superior CBD product that is full spectrum without depending on THC to activate the benefits of cannabidiol. Black Pearl CBD has 0% THC, but is not an Isolate where the THC is stripped from the product rendering it ineffective. We use a proprietary technique adding terpenes as the activation ingredient, resulting in a product that is the finest in the industry. Products are available and look for a new updated website soon at www.blackpearlcbd.com.
Information contained herein includes forward-looking statements. These statements relate to future events or future financial performance, involving known and unknown risks and you should not place undue reliance on these statements. Any forward-looking statement reflects our current views with respect to future events. We assume no obligation publicly about update or revise these forward-looking statements for any reason.
It seems as though we learn more about cannabinoids with every day that passes. Looking back 5 years, the only two cannabinoids most of us could name are CBD and THC. However, in the more recent history, we now hear about the powers of CBG, CBN, THCVA, THCV, and many more – which we can credit to increased mainstream acceptance that cannabis is in fact, medicine. Contextually, if we think about THCA, which is the acid form of THC, activated by decarboxylation, becomes THC. In the same sense, CBDA is the acid form of CBD and like CBD, CBDA is not psychoactive, so don’t expect it to provide a “high.” With a friendly reminder that we are not clinicians, you should always seek a qualified physician’s counsel when determining the effectiveness of CBDA for your conditions.
Thus far, research has suggested that CBDA could be useful in treating anxiety and depression, both of which are typically treated with pharmaceuticals. The body metabolizes CBDA faster and with more efficiency than CBD, and CBDA apparently clings to our serotonin receptors – which are the responsible parts of our bodies that make us feel content, comfortable, and emotionally stable. Like CBD, research also indicates that inflammation and chronic pain are also receptive to CBDA in terms of pain reduction but also prevent nerve and tissue damage. GW Pharmaceuticals, most well known for being the first cannabis based prescription medication for epilepsy, are studying CBDA as an anti-nausea treatment, and potentially as another anti-seizure treatment.
If you’re looking for CBDA on product labels, don’t waste your time. With research in its infancy for CBDA’s benefits, it’s not yet an ingredient touted openly. But you can find it in cannabis flower that’s listed “high CBD” or “CBD-rich” – consider Charlotte’s Web or Harlequin. If you smoke these flowers, you’ll turn the CBDA into CBD, which is not a bad thing, but in order to enjoy CBDA itself, you can consider consuming it raw in a smoothie or juiced. If you’re really adventurous and a whiz with cold extraction, you could also extract it as a concentrate.
We’ll look forward to the next advancements in research about CBDA as well as other cannabinoids as we continue to learn more with sanctioned research into the magical plant medicine we call cannabis.
This November, pot stocks enjoyed renewed interest from investors. In a continuing scramble to see which company will capitalize on the recently legalized „cannabis 2.0” (derivatives) market in Canada, the United States’ green wave also showed new life. Last month, voters in four states — New Jersey, Arizona, South Dakota, and Montana — cast their ballots to legalize recreational cannabis, and President-elect Joe Biden put decriminalization on his administration’s agenda.
Two pot stocks investors are contemplating are Canopy GrowthCorp (NASDAQ:CGC) and Aurora Cannabis(NYSE:ACB). In the past month, both stocks made some investors rich, with the former up 54% and the latter on a monstrous rally that yielded a 154% gain. Many factors are pointing toward further gains for Aurora, and that Canopy may be overvalued. Let’s take a look at them below.
Image source: Getty Images.
The quick case for Canopy Growth
Let’s be honest: Canopy had a blowout quarter in its second quarter 2021, which ended Sept. 30. During this period, the company increased its revenue by a stunning 77% year over year to CA$135.3 million. At the same time, it expanded its gross margins from 5% to 19%. There was also a 57% improvement in the company’s free cash flow, declining to a loss of $190.4 million per quarter.
Canopy Growth holds a dominant market share of 54% in the cannabis beverages industry. In addition, it managed to improve its standing in the Canadian recreational cannabis market by increasing its industry weight to 15.5%, a two-percentage-point improvement over first-quarter 2021.
In context, however, Canopy Growth’s potential is mostly priced-in. Right now, the stock trades at a whopping 28 times sales, making it one of the most expensive stocks in the entire North American cannabis industry. Those with a value mindset, or those who just don’t like to pay a high premium for good growth stocks, should take a look at its cheaper cousin, Aurora Cannabis, instead.
Why Aurora Cannabis is better
Aurora Cannabis’ stock is very oversold. In 2019, the company expanded its production capacity to over 500,000 kilograms of cannabis per year. As of Q1 2021 (ended Sept. 30), however, the company found there was only demand for about 64,000 kilograms of its pot each year. Due to dramatically miscalculating the supply-and-demand balance of Canada’s legal cannabis market, Aurora had to write down billions in losses on its assets.
One thing that amazes me about Aurora, however, is the speed of its turnaround. After a series of facility closures and lay-offs, Aurora is on track to resize its operations. In Q1 2021, its revenue decreased slightly to CA$67.8 million. However, the company managed to post an adjusted gross margin of 52%, far better than Canopy Growth’s 19%.
Aurora cut its sales, general, and administrative (SG&A) expenses from CA$100 million per quarter to CA$43 million per quarter within the span of a year. Its operating loss adjusted for non-cash items (EBITDA) stands at only CA$10.5 million.
These cost-cutting measures are working well. They are aided by the fact that Aurora is slowly realizing new sales potential. In May, the company acquired U.S. cannabidiol (CBD) producer, Reliva. This subsidiary holds the top-selling cannabinoid topical cream and the second most popular CBD brands overall (by some measures) in the nation. Before its acquisition, Reliva brought in about $10 million per year in sales.
Reliva’s products are available online and in over 20,000 retail locations. Nearly half of America’s biggest convenience stores sell the company’s CBD. As more and more states join the legalization bandwagon, one should expect Reliva’s sales (and, by proxy, Aurora’s) to accelerate in the near future.